HCAT Stock Overview
Provides data and analytics technology and services to healthcare organizations in the United States. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Health Catalyst, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$7.09 |
52 Week High | US$11.41 |
52 Week Low | US$5.42 |
Beta | 1.33 |
1 Month Change | -3.67% |
3 Month Change | -18.41% |
1 Year Change | -25.91% |
3 Year Change | -82.04% |
5 Year Change | -79.23% |
Change since IPO | -81.90% |
Recent News & Updates
Health Catalyst: Improved Demand Environment Reinforces My Buy Rating
Dec 18Health Catalyst: Still Optimistic On Achieving Adjusted EBITDA Targets
Sep 24Recent updates
Health Catalyst: Improved Demand Environment Reinforces My Buy Rating
Dec 18Health Catalyst: Still Optimistic On Achieving Adjusted EBITDA Targets
Sep 24Health Catalyst, Inc.'s (NASDAQ:HCAT) Shares Lagging The Industry But So Is The Business
Jul 17Health Catalyst: Stellar Earnings Growth Projected
Jun 26Health Catalyst, Inc. (NASDAQ:HCAT) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 12Benign Growth For Health Catalyst, Inc. (NASDAQ:HCAT) Underpins Its Share Price
Apr 04Health Catalyst: Achieving FY28 Long-Term Guidance Is Possible
Mar 09Health Catalyst Looks To Slim Down As It Faces Industry Headwinds (Downgrade)
Feb 16Is Health Catalyst (NASDAQ:HCAT) A Risky Investment?
Jan 27What Health Catalyst, Inc.'s (NASDAQ:HCAT) 25% Share Price Gain Is Not Telling You
Dec 24Is Health Catalyst, Inc. (NASDAQ:HCAT) Trading At A 47% Discount?
Dec 15Is Health Catalyst (NASDAQ:HCAT) Weighed On By Its Debt Load?
Oct 24Subdued Growth No Barrier To Health Catalyst, Inc.'s (NASDAQ:HCAT) Price
Jul 31Is Health Catalyst (NASDAQ:HCAT) Using Too Much Debt?
Jun 27Is Health Catalyst (NASDAQ:HCAT) Using Too Much Debt?
Feb 22Health Catalyst, Inc. (NASDAQ:HCAT) Shares Could Be 22% Above Their Intrinsic Value Estimate
Dec 06Is Health Catalyst (NASDAQ:HCAT) Using Debt In A Risky Way?
Nov 03Health Catalyst: Looking For A Turnaround For This 'Bio Boom' Candidate
Oct 14Health Catalyst names Kevin Freeman as Chief Growth Officer, Tarah Bryan as Chief Marketing Officer, Dave Ross as Chief Technology Officer
Sep 07Shareholder Returns
HCAT | US Healthcare Services | US Market | |
---|---|---|---|
7D | -11.3% | -3.7% | -3.5% |
1Y | -25.9% | 0.7% | 22.1% |
Return vs Industry: HCAT underperformed the US Healthcare Services industry which returned 0.7% over the past year.
Return vs Market: HCAT underperformed the US Market which returned 22.1% over the past year.
Price Volatility
HCAT volatility | |
---|---|
HCAT Average Weekly Movement | 8.0% |
Healthcare Services Industry Average Movement | 9.5% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 17.0% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HCAT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HCAT's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 1,300 | Dan Burton | www.healthcatalyst.com |
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
Health Catalyst, Inc. Fundamentals Summary
HCAT fundamental statistics | |
---|---|
Market cap | US$424.11m |
Earnings (TTM) | -US$79.14m |
Revenue (TTM) | US$302.06m |
1.4x
P/S Ratio-5.5x
P/E RatioIs HCAT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
HCAT income statement (TTM) | |
---|---|
Revenue | US$302.06m |
Cost of Revenue | US$162.59m |
Gross Profit | US$139.47m |
Other Expenses | US$218.61m |
Earnings | -US$79.14m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.30 |
Gross Margin | 46.17% |
Net Profit Margin | -26.20% |
Debt/Equity Ratio | 97.2% |
How did HCAT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/20 23:12 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Health Catalyst, Inc. is covered by 22 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Zhilin Long | Berenberg |
David Larsen | BTIG |
Richard Close | Canaccord Genuity |